Key Points for Decision Makers {#FPar1}
==============================

Treatment of overactive bladder (OAB) with mirabegron 50 mg in the UK may result in lower healthcare resource utilization, lost productivity costs, and overall treatment costs compared with antimuscarinics.Further work is needed to confirm these findings in different populations to assess the effects of mirabegron on the costs of treatment in other countries.

Introduction {#Sec1}
============

Overactive bladder (OAB) is characterized by urinary urgency, usually with urinary frequency and nocturia, with or without urinary incontinence \[[@CR1]\]. OAB affects up to 17% of adults aged ≥40 years in Europe and up to 17% of all adults in the USA \[[@CR2], [@CR3]\]. In Europe, a higher proportion (30--40%) of OAB is observed in adults  ≥75 years of age \[[@CR2]\].

The clinical and economic burden of OAB is significant. Symptoms of OAB have been reported to adversely affect patients' daily activities, sleep, mental health and personal relationships \[[@CR4], [@CR5]\]. These symptoms also have a significant impact on productivity in the workplace and healthcare resource use \[[@CR6]\]. In the UK, the total direct economic impact (incremental costs) of OAB on the national healthcare system is estimated to be in excess of £1 billion \[[@CR6]\].

Following the use of conservative management strategies, treatment with pharmacotherapy can result in symptom improvement. However, bothersome on-treatment adverse events (AEs) from antimuscarinic agents (such as dry mouth and constipation) are common because of a lack of target organ specificity \[[@CR7]\]. Side effects observed with antimuscarinics may also have deleterious effects on treatment persistence. A screening survey conducted in the USA identified 6577 patients with one or more antimuscarinic prescriptions for OAB \[[@CR8]\]. Of the 1322 patients who reported discontinuing treatment prior to follow-up, 1177 (89%) discontinuations were primarily due to unmet treatment expectations and/or tolerability \[[@CR8]\].

Mirabegron is a first-in-class licensed selective oral β~3~-adrenoceptor agonist approved in the UK for the treatment of OAB \[[@CR9]\]. It promotes bladder relaxation of the detrusor muscle during the storage phase, improving bladder capacity \[[@CR10]\]. Mirabegron demonstrated overall efficacy similar to that of antimuscarinic therapies in clinical trials \[[@CR11]\] but with an improved overall tolerability profile \[[@CR11], [@CR12]\]. Evidence from a recent retrospective analysis of prescription claims in Canada demonstrated that, over a 12-month period, patients with OAB treated with mirabegron have improved persistence compared with those treated with antimuscarinics \[[@CR13]\].

A prospective study of women with OAB who received treatment with fesoterodine for 8 weeks also showed that those who adhered to treatment reported significantly greater improvements in clinical symptoms at the end of the treatment period than those who were non-adherent \[[@CR14]\]. In addition, persistence with treatment has been shown to reduce consumption of healthcare resources in OAB \[[@CR15]\]. Given the impact of OAB on work absenteeism and productivity \[[@CR6]\], persistence and symptom control may be expected to reduce the impact of these factors.

This study aimed to use predominantly real-world evidence to estimate the economic outcomes associated with persistence with mirabegron treatment versus antimuscarinic agents in patients with OAB in the UK.

Methods {#Sec2}
=======

Model Overview {#Sec3}
--------------

This is a Microsoft^®^ Excel-based (version 17.0, Microsoft Corporation, Redmond, WA, USA) Markov model. The time horizon is 12 months, the cycle length is 1 month and the default cohort size is 100 patients. Mirabegron 50 mg/day is compared with the following antimuscarinic treatments (all doses reported are per day): fesoterodine 4/8 mg, oxybutynin extended release (ER) 5 mg, oxybutynin immediate release (IR) 5 mg, solifenacin 5/10 mg, tolterodine ER or IR both 4 mg, trospium ER 60 mg or IR 40 mg, darifenacin 7.5 mg, and flavoxate 600 mg.

The base-case analysis provided a societal perspective of OAB management by accounting for all costs incurred by the UK NHS as well as those associated with lost productivity. Patient disposition, healthcare resource use, direct costs, indirect costs and total costs were all assessed as part of the base-case analysis.

Treatment Pathway {#Sec4}
-----------------

Patients enter the model in the 'persistence on treatment' health state (Fig. [1](#Fig1){ref-type="fig"}) and are assigned to treatment with mirabegron 50 mg (the recommended approved dose in the UK \[[@CR9]\]) or an antimuscarinic agent (Fig. [2](#Fig2){ref-type="fig"}). At the end of each month, patients either persist with treatment or discontinue. Those who discontinue initial treatment switch to an alternative pharmacological intervention, undergo surgical operations (onabotulinumtoxinA injection or sacral nerve stimulation \[SNS\]) or discontinue treatment altogether. Patients can transition to other treatment states or death at each cycle. To make the analysis tractable within a 12-month time horizon, the model assumes that switching to a second-line pharmacotherapy and undergoing surgical operations both lead to symptom control (with no option for additional lines of treatment) until the end of the time horizon. Patients who discontinue treatment altogether are assumed to remain uncontrolled. Other model assumptions are reported in Table [1](#Tab1){ref-type="table"}.Fig. 1Markov model structure *tx* treatment Fig. 2Treatment pathway Table 1Model assumptionsNon-persisters were assumed to either switch, undergo surgical operations or remain uncontrolledSwitchers and patients having surgical operations were assumed to have controlled symptomsAt treatment initiation (the start of the model), all patients were assumed to incur one visit to a GP and 1.5 visits to a specialist (urologist) \[[@CR17]\]Switchers were assumed to have one GP visit, 1.5 visits to a specialist (urologist) and one urodynamic test \[[@CR17]\]Patients who switched treatment were ascribed a drug acquisition cost, which was weighted by the market share of each treatment. The market share data were provided by Astellas \[[@CR24]\]One total probability of surgical operations was included and costs were applied \[[@CR19]\], assuming that 50% of patients had onabotulinumtoxinA injection and 50% had SNSOnly non-persisters with uncontrolled symptoms were assumed to be at risk of co-morbidities (depression and UTI) \[[@CR25]\]; the risk was applied in each cyclePatients who were non-persistent and uncontrolled were assumed to have a 21.1% decrease in hours worked \[[@CR25]\]The persistence at 12 months was assumed to be the same for each treatment irrespective of the dose received \[[@CR16]\]The persistence at 12 months was assumed to be the same for trospium ER and IR formulations, and tolterodine ER and IR \[[@CR16]\]*ER* extended release, *GP* general practitioner, *IR* immediate release, *SNS* sacral nerve stimulation, *UTI* urinary tract infection

Model Input Parameters {#Sec5}
----------------------

### Clinical Inputs {#Sec6}

We derived 12-month persistence data (Table [2](#Tab2){ref-type="table"}) from a retrospective database study conducted in the UK \[[@CR16]\]. In addition, the treatment switching rate (26.06%) was taken from a previously published cost-effectiveness analysis of mirabegron compared with antimuscarinics for the treatment of adults with OAB in the UK \[[@CR17]\]. Mortality for the population with OAB was based on the UK age-standardized general population mortality rate \[[@CR18]\] and converted to a 1-month probability (*P*) using the formula: *P* = 1 − e^*−rt*,^ where *r* represents rate and *t* time.Table 2Clinical inputsVariableValue (%)SourceProportion of patients with incontinence60.00Nitti et al. \[[@CR22]\]^a^Percentage of patients switching treatment26.06Nazir et al. \[[@CR17]\]12-month persistence (UK CPRD) Mirabegron 50 mg37.70Astellas \[[@CR16]\] Fesoterodine 4/8 mg24.00Astellas \[[@CR16]\] Oxybutynin ER 5 mg17.20Astellas \[[@CR16]\] Oxybutynin IR 5 mg12.40Astellas \[[@CR16]\] Solifenacin 5/10 mg24.80Astellas \[[@CR16]\] Tolterodine ER 4 mg20.60Astellas \[[@CR16]\] Tolterodine IR 4 mg20.60Astellas \[[@CR16]\] Trospium ER 60 mg19.10Astellas \[[@CR16]\] Trospium IR 40 mg19.10Astellas \[[@CR16]\] Darifenacin 7.5 mg15.90Astellas \[[@CR16]\] Flavoxate 600 mg8.30Astellas \[[@CR16]\]General population mortality0.97ONS \[[@CR18]\]*CPRD* Clinical Practice Research Datalink, *ER* extended release, *IR* immediate release, *ONS* Office for National Statistics^a^A conservative estimate of 60% was applied to the model based on 65.7% of the total population who were reported to have urgency or mixed incontinence at baseline. All doses reported are the total dose per day

### Healthcare Resource Use {#Sec7}

Costs associated with resource use such as general practitioner (GP) and specialist visits were derived from NHS data \[[@CR19]--[@CR21]\]. Unit costs were calculated/estimated for one GP visit and 1.5 referrals to a urologist at treatment initiation and treatment switch (Table [3](#Tab3){ref-type="table"}) \[[@CR17]\]. One test by a specialist clinician (e.g. urologist, gynaecologist or other) was performed for each patient who switched to a second-line pharmacotherapy \[[@CR17]\]. The proportion of patients with incontinence and requiring pads was estimated to be 60% based on the number of patients with wet OAB \[[@CR22]\]. Pad use was estimated to be 2.5 pads per day for patients on treatment (i.e. persisters and switchers) and 5.5 pads per day for those off treatment (i.e. those who underwent surgical operations or discontinued all treatment) \[[@CR19]\].Table 3Resource inputsParameterValue or probabilityUnit costSourceDrug acquisitionCost per day (£)First-line pharmacotherapy-- Mirabegron 50 mg--0.97BNF 71 \[[@CR23]\] Fesoterodine 4/8 mg--0.92BNF 71 \[[@CR23]\] Oxybutynin ER 5 mg--0.46BNF 71 \[[@CR23]\] Oxybutynin IR 5 mg--0.07BNF 71 \[[@CR23]\] Solifenacin 5/10 mg^a^--1.00BNF 71 \[[@CR23]\] Tolterodine ER 4 mg--0.92BNF 71 \[[@CR23]\] Tolterodine IR 4 mg--0.09BNF 71 \[[@CR23]\] Trospium ER 60 mg--0.82BNF 71 \[[@CR23]\] Trospium IR 40 mg--0.83BNF 71 \[[@CR23]\] Darifenacin 7.5 mg--0.91BNF 71 \[[@CR23]\] Flavoxate 600 mg--0.39BNF 71 \[[@CR23]\]Second-line pharmacotherapy^b^--0.64BNF 71 \[[@CR23]\], Astellas \[[@CR24]\]Surgical operations^c^0.01%1242.59Visits/test GP146.89Nazir et al. \[[@CR19]\]; PSSRU \[[@CR21]\] Urologist1.5102.16Nazir et al. \[[@CR19]\]; UK Department of Health Urodynamic test1282.00Nazir et al. \[[@CR19]\]; South Devon Healthcare \[[@CR30]\]PadsCost per pad (£) On treatment2.5/day0.25Nazir et al. \[[@CR19]\]; Incontinence Direct \[[@CR31]\] Off treatment5.5/day0.25Nazir et al. \[[@CR19]\]; Incontinence Direct \[[@CR31]\]Co-morbidities Depression19.0%^d^99.10Arlandis-Guzman et al. \[[@CR25]\]; Irwin et al. \[[@CR6]\] UTI30.7%^d^2.79Arlandis-Guzman et al. \[[@CR25]\]; Irwin et al. \[[@CR6]\]All doses reported are the total dose per day*BNF* British National Formulary, *ER* extended release, *GP* general practitioner, *IR* immediate release, *OAB* overactive bladder, *UTI* urinary tract infection^a^Weighted average of solifenacin 5 mg (70%) and 10 mg (30%); unit costs of 30 tablet packs of £27.62 and £35.91, respectively^b^Weighted cost based on market share of oral therapies for OAB^c^Weighted cost based on a 50:50 ratio of onabotulinumtoxinA and sacral nerve stimulation^d^6-month probability; unit costs based on 2005 monthly costs, converted to 2015 values using the UK forex exchange rate (as of October 2015)

Drug acquisition costs were calculated based on the treatment cost per pack (Table [3](#Tab3){ref-type="table"}) \[[@CR23]\] and were correct as of quarter 1, 2016. The cost of second-line pharmacotherapy was based on a weighted average derived from UK market share data \[[@CR24]\].

Patients who were uncontrolled were considered to be at risk of two co-morbidities: depression and urinary tract infection (UTI). The 6-month probabilities of depression and UTI were 18.8 and 30.7%, respectively \[[@CR25]\], and the monthly probability of surgical operations was 0.01% \[[@CR17]\].

The costs for all resources were based on 2015 values, or inflated to 2015 values using the consumer price index (CPI) where applicable. The costs of depression and UTI sourced from Irwin et al. \[[@CR6]\] were converted from € to British ₤ using the UK Forex exchange rate (as of December 2015).

### Loss of Productivity {#Sec8}

The model accounts for loss of work productivity only in patients who are non-persistent with treatment, have uncontrolled symptoms and are in employment. The base-case analysis assumed that 34.7% of the patients were employed for an average of 40 h per week \[[@CR25], [@CR26]\], had uncontrolled OAB and had a 21.1% reduction in the hours worked \[[@CR25]\]. The average hourly wage of £12.62 (2011 value) was inflated to £13.94 (2015 value) using the CPI \[[@CR27]\].

Sensitivity Analysis {#Sec9}
--------------------

A one-way univariate deterministic sensitivity analysis (DSA) was performed to assess the uncertainty of chosen parameters \[[@CR28]\]. Here, a standard 20% variation in the following model parameters was tested individually and the effects on the incremental costs determined: persistence at 12 months, percentage of patients switching and probability of surgical operations. Mirabegron 50 mg was compared with solifenacin 5/10 mg and oxybutynin IR 5 mg. The results of the DSA were presented as a tornado diagram, with the parameters that had the greatest impact at the top.

Results {#Sec10}
=======

Patient Disposition {#Sec11}
-------------------

After 12 months, more patients persisted on treatment with mirabegron 50 mg than with all antimuscarinics (39 vs. 9--26%, respectively \[values for all antimuscarinics presented as a range\]) (Fig. [3](#Fig3){ref-type="fig"}). This resulted in fewer patients either switching treatment (16 vs. 19--23%, respectively) or becoming non-persistent uncontrolled patients (44 vs. 54--66%, respectively).Fig. 3Summary of patient disposition after 12 months for each treatment. Total disposition may not sum to 100% because of rounding. All doses reported are the total dose per day. *ER* extended release, *IR* immediate release

Healthcare Resources {#Sec12}
--------------------

Resource use was lower with mirabegron 50 mg than with all antimuscarinics, including GP visits (115 vs. 119--123, respectively, per 100 patients), specialist visits (173 vs. 178--185, respectively, per 100 patients) and number of surgical operations (0.0042 vs. 0.0050--0.0060, respectively, per 100 patients) (Table [4](#Tab4){ref-type="table"}). Total pad use per patient over 12 months was also lower with mirabegron 50 mg than with all antimuscarinics (71,807 vs. 76,531--84,602, respectively, per 100 patients) (Fig. [4](#Fig4){ref-type="fig"}).Table 4Healthcare resource use over 12 monthsResult parameterMirabegron 50 mgFesoterodine 4/8 mgOxybutynin ER 5 mgOxybutynin IR 5 mgSolifenacin 5/10 mgTolterodine ER 4 mgTolterodine IR 4 mgTrospium ER 60 mgTrospium IR 40 mgDarifenacin 7.5 mgFlavoxate 600 mgGP visits115119121122119120120120120121123Specialist visits173178181183178180180180180182185Surgical operations0.00420.00510.00550.00580.00500.00530.00530.00540.00540.00560.0060Total pad use71,80776,85379,79882,19476,53178,27478,27478,93278,93280,41484,602 On treatment40,12335,91833,46431,46736,18734,73434,73434,18634,18632,95029,461 Off treatment31,68440,93446,33450,72740,33443,54043,54044,74744,74747,46455,142All doses reported are the total dose per day*ER* extended release, *GP* general practitioner, *IR* immediate release Fig. 4Total pad use per 100 patients, after 12 months for each treatment. All doses reported are the total dose per day. *ER* extended release, *IR* immediate release

Direct Costs {#Sec13}
------------

Mirabegron 50 mg had a higher medication cost than all antimuscarinics (£24,744 vs. 4599--22,634 per 100 patients) (Table [5](#Tab5){ref-type="table"}). However, resource use costs, including those for the co-morbidities of depression and UTI, GP visits, specialist visits, surgical operations, urodynamic tests and pads, were lower with mirabegron than with all antimuscarinics (Table [5](#Tab5){ref-type="table"}).Table 5Total direct costs over 12 months for each treatmentCost (£)Mirabegron 50 mgFesoterodine 4/8 mgOxybutynin ER 5 mgOxybutynin IR 5 mgSolifenacin 5/10 mgTolterodine ER 4 mgTolterodine IR 4 mgTrospium ER 60 mgTrospium IR 40 mgDarifenacin 7.5 mgFlavoxate 600 mgAll medication24,74420,81011,124459922,63420,004467717,87517,90718,6099104 First line22,58618,0227969114519,88617,038171214,82714,85915,3775349 Second line21582788315534552748296529653047304732323755Co-morbidities11211448163917951427154015401583158316791951GP visits54085577566457275567562056205639563956805782Specialist visits17,67418,22618,50918,71518,19318,36718,36718,42918,42918,56518,897Surgical operations5.196.306.837.186.246.576.576.686.686.937.45Urodynamic tests43265342586362435281560156015716571659656577Total pad use17,82419,07619,80720,40218,99619,42919,42919,59219,59219,96020,999 On treatment99598915830678118982862186218485848581797313 Off treatment786410,16111,50112,59110,01410,80710,80711,10711,10711,78113,687All doses reported are the total dose per day*ER* extended release, *GP* general practitioner, *IR* immediate release

Indirect Costs {#Sec14}
--------------

The number of work hours lost (4017 vs. 5114--6990 per 100 patients) and the cost due to work hours lost (£55,983 vs. 71,284--97,430 per 100 patients) were both lower with mirabegron 50 mg than with all antimuscarinics (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Total work hours lost over 12 months and associated costs for each treatment per 100 patients. All doses reported are the total dose per day. *ER* extended release, *IR* immediate release

Total Costs {#Sec15}
-----------

Total costs were lower for mirabegron 50 mg than for all antimuscarinics (£127,084 vs. 132,171--160,748, respectively, per 100 patients) (Fig. [6](#Fig6){ref-type="fig"}). This translated into lower respective total costs per patient (£1271 vs. 1322--1607) and per patient per day (£3.48 vs. 3.62--4.40).Fig. 6Total costs (including indirect costs) over 12 months for each treatment per 100 patients. All doses reported are the total dose per day. *ER* extended release, *IR* immediate release

Sensitivity Analysis {#Sec16}
--------------------

For both comparisons, the model was most sensitive to ± 20% changes in persistence rates for either treatment and the percentage of patients switching (Fig. [7](#Fig7){ref-type="fig"}). The incremental cost savings per patient per day were −£0.45 in the base-case analysis of mirabegron 50 mg versus solifenacin 5/10 mg and −£0.55 versus oxybutynin IR 5 mg. The overall impact was similar when the incremental cost savings per additional patient persisting on treatment were assessed (Fig. S1 in the Electronic Supplementary Material).Fig. 7Results of the deterministic sensitivity analysis for mirabegron 50 mg versus **a** solifenacin 5/10 mg and **b** oxybutynin IR 5 mg (incremental cost per patient per day). All doses reported are the total dose per day. *IR* immediate release

Discussion {#Sec17}
==========

To our knowledge, this model is the first to estimate the economic impact of using mirabegron 50 mg versus antimuscarinic agents for the treatment of OAB from a societal perspective in the UK, largely employing real-world data (specifically persistence rates).

According to the model, after 12 months, more patients receiving mirabegron 50 mg versus all antimuscarinics persisted with treatment, fewer patients switched treatment and fewer work hours were lost. Although mirabegron 50 mg had higher medication costs over 12 months than did antimuscarinics, these costs were offset by savings attributed to other direct and indirect costs. This was partly attributable to a lower proportion of non-persisters and switchers, who had higher demand for healthcare resources and higher pad use than patients who persisted with treatment. The results suggest that more patients in the UK who receive mirabegron will persist with first-line pharmacological treatment versus antimuscarinics over 12 months, resulting in more patients with likely controlled symptoms. Administration of mirabegron as first-line pharmacotherapy for OAB could have beneficial effects in terms of lower resource use and overall treatment, containment of healthcare costs and societal benefit. Furthermore, while lower healthcare resource use has been cited as a benefit of increased treatment persistence \[[@CR15]\], better persistence rates could also be expected to improve patient quality of life (QoL), likely because of increased symptom control and an increased ability to continue daily activities \[[@CR15]\]. This model did not include the likely improvements in QoL for those who persist with treatment.

While similar efficacy is observed between mirabegron and antimuscarinics \[[@CR11]\], real-world evidence indicates that a higher proportion of patients are likely to be non-persistent with treatment with antimuscarinics versus mirabegron 50 mg \[[@CR13]\]. Potential reasons for treatment discontinuation with antimuscarinics include bothersome AEs such as dry mouth and constipation, the most common AEs in these patients \[[@CR7]\]. A recent systematic literature review and network meta-analysis of mirabegron 50 mg versus antimuscarinics in 27,309 patients with OAB reported a similar incidence of dry mouth for mirabegron 50 mg and placebo but a lower incidence for mirabegron 50 mg versus all antimuscarinics assessed \[[@CR11]\]. These findings may be reflected in the present study, as healthcare resource use was lower for mirabegron 50 mg than for all antimuscarinics, with fewer associated costs. However, it should be noted that treatment discontinuation can be attributed to many factors, and a greater overall focus should be applied to tailoring OAB treatment to the individual.

The primary strengths of this model are that it utilizes real-world data related to treatment of OAB and healthcare resource use in the UK. Therefore, the total costs derived for mirabegron versus antimuscarinics are based on effectiveness rather than efficacy. However, the findings that suggest a benefit of mirabegron (if used as first-line pharmacotherapy for OAB) depend on the several key assumptions made in the model, such as persistence at 12 months being independent of the treatment dose received and persistence not varying between trospium ER and IR and tolterodine ER and IR. Furthermore, all patients who switch treatment or undergo surgical operations are assumed to have controlled symptoms, and this would be variable. Structural edits to the model would be required to account for these factors if additional sensitivity analyses were to be performed. As OAB is a chronic condition, provision of a longer time horizon would be beneficial to accurately estimate the economic benefits of long-term treatment. Another limitation is that no direct clinical data for estimates of efficacy, tolerability or health-related QoL were included; therefore, some patient perspectives were not captured. With respect to the treatment comparators, the model includes the most common treatment options for OAB in the UK according to the results of a retrospective analysis of a clinical practice database \[[@CR16]\]; this included flavoxate, which is not recommended for use in women with urinary incontinence in the UK \[[@CR29]\].

Although the model does not account for persistence in different subgroups of patients, results were largely consistent with the total study population, and few differences in persistence between subgroups were observed in a Canadian study of persistence with mirabegron 50 mg versus antimuscarinics over 12 months (the only notable difference was that patients were more likely to persist as the number of co-existing prescribed medications increased \[up to more than eight\]) \[[@CR13]\]. Whether differences between subgroups would be observed if the model were updated to allow these kinds of analyses is unclear. The persistence data used in the model were taken from a large non-interventional study conducted in the UK \[[@CR16]\]; patient demographics in this study were generally well-balanced across treatment groups, although significantly more patients receiving mirabegron were female, treatment-experienced and receiving co-existing medications compared with those receiving the primary comparator treatment (tolterodine ER).

Conclusions {#Sec18}
===========

This model suggests that treatment of OAB in the UK with mirabegron 50 mg will result in more patients persisting with treatment and lower total costs of treatment versus antimuscarinics. Further work is needed to confirm these findings in different populations to assess the effect of mirabegron on persistence and overall treatment costs in other countries.

Electronic supplementary material
=================================

 {#Sec19}

Below is the link to the electronic supplementary material. Supplementary material 1 (EPS 3433 kb) Supplementary Fig. 1 Results of the deterministic sensitivity analysis (a) for mirabegron 50 mg versus solifenacin 5/10 mg; and (b) for mirabegron 50 mg versus oxybutynin IR 5 mg (cost per additional patient persisting on treatment). All doses reported are the total dose per day. *IR* immediate release
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